Japan
Korea
Over 30 pre-qualified patients will receive treatment with the Vbeam Pulsed Dye Laser to commence the Vascular Birthmarks Foundation's 18th Annual Conference.
WAYLAND, Mass., Sept. 26, 2018 /PRNewswire/ -- Candela Corporation, a leading global manufacturer of energy-based devices, announces it will be partnering with the Vascular Birthmarks Foundation (VBF) to provide pro-bono Vbeam laser treatments to children and adults with birthmarks, port wine stains and other vascular related skin conditions as a kickoff to the VBF 18th Annual Conference. The treatments will be performed at the Laser & Skin Surgery Center of New York in Manhattan on Friday, October 5 by the center's director, Dr. Roy Geronemus.
"Candela is committed to developing and enhancing innovative technological solutions that change lives. Our partnership with the Vascular Birthmarks Foundation and Dr. Roy Geronemus reflects this commitment," states Geoffrey Crouse, Chief Executive Officer of Candela. "We are honored to offer these pro-bono treatments with the gold standard Vbeam Pulsed Dye Laser (PDL) to continue our mission to improve patients' quality of life. The recent FDA clearance of our newest and most advanced Pulsed Dye Laser, the Vbeam Prima, demonstrates our continued 30-year commitment to advancing the science and improving clinical results in vascular lesions."
One in ten children are born with a vascular birthmark. The Vbeam PDL is considered the gold-standard for the treatment of port wine stains and vascular anomalies in infants and children, as well as adults. Used by healthcare providers and close to 700 universities and hospitals worldwide, the device is associated with life changing outcomes, high patient tolerability and a low incidence of side effects.
"Vascular lesions, especially those on the face, have serious physical and psychological effects on patients," said Dr. Geronemus. "I am honored to be a part of the effort to provide patients with this life changing treatment. The Vbeam is without a doubt an incredibly safe and effective treatment for these conditions."
Following the Vbeam treatments scheduled for October 5, the Vascular Birthmarks Foundation Annual Conference will take place all day on Saturday, October 6 at Lenox Hill Hospital. The conference will offer educational sessions on the latest research and advancements in treatments for vascular birthmarks, including port wine stains, hemangiomas, and related conditions. Experts will also be available to meet with families throughout the day for sessions on makeup, psychotherapy, insurance issues and support. Candela is proud to be a key sponsor of this annual initiative.
"Living with a birthmark or other vascular formation can have significant consequences on a patient's life. It's crucial that we educate those who are impacted, as well as the physicians who treat these conditions, on the latest protocols available," said Dr. Linda Rozell-Shannon, President & Founder of the Vascular Birthmarks Foundation. "We have many patients that are eager to receive treatment, and we are grateful that Candela and Dr. Geronemus are working with us to make it possible."
For more information about Candela or the Vbeam Pulsed Dye Laser, please visit https://candelamedical.com/
For more information about vascular formations or the Vascular Birthmarks Foundation, please visit www.birthmark.org.
Candela Corporation is a leading global medical aesthetic device company with an extensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical aesthetic applications including hair removal; wrinkle reduction; tattoo removal; women's health treatments; facial resurfacing; traumatic and surgical scar treatments; body contouring; improving the skin's appearance through the treatment of benign vascular and pigmented lesions; and the treatment of acne, leg veins, and cellulite. Candela has a wide portfolio of trusted, leading products, including the Vbeam®, Gentle® Family, CO2RE®, CO2RE Intima®, Exceed™, Nordlys™, Frax Pro™, Profound®, PicoWay®, and VelaShape®, as well as other energy-based platforms. Acquired by Apax Partners in July 2017, the Company markets, services and supports its products in over 100+ countries. It has offices in the United States, Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom, and many international distributors.
The Vascular Birthmarks Foundation (VBF) is an international charitable organization that networks families affected by a vascular birthmark, tumor, or syndrome to the appropriate medical professionals for evaluation and/or treatment, provides informational resources as well as sponsors physician education, mobilizes medical missions trips, and supports research and programs that promote acceptance for individuals with birthmarks. VBF has networked over 125,000 children and adults into treatment since 1994. For more information, go to www.birthmark.org.
EvolveMKD
P: 646.517.4220 | E: candela@evolvemkd.com
SOURCE Candela